Squamous Cell Carcinoma

Oncology
10
Pipeline Programs
9
Companies
23
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
8
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
250%
Small Molecule
250%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
2 programs
2
AtezolizumabPhase 2Monoclonal Antibody
ErlotinibPhase 2Small Molecule
Alliance Pharmaceuticals
2 programs
2
AtezolizumabPhase 2Monoclonal Antibody4 trials
ErlotinibPhase 2Small Molecule5 trials
Active Trials
NCT06762808Withdrawn0Est. Aug 2025
NCT06754501Active Not Recruiting4Est. Jul 2029
NCT05798663Active Not Recruiting178Est. Nov 2026
+6 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Afatinib 40 MGPhase 21 trial
Active Trials
NCT05070403Recruiting25Est. Mar 2028
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Injection of TVEC into target lesions - week 1-2Phase 21 trial
Active Trials
NCT03714828Completed11Est. Jul 2023
Karyopharm Therapeutics
1 program
1
SelinexorPhase 21 trial
Active Trials
NCT02213133TerminatedEst. Dec 2015
Coherus Oncology
Coherus OncologyCA - Redwood City
1 program
1
Toripalimab-tpziPhase 21 trial
Active Trials
NCT07214987Not Yet Recruiting26Est. Sep 2029
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
Aldoxorubicin HClPhase 1/21 trial
Active Trials
NCT03387111Terminated4Est. Jan 2021
Sanofi
SanofiPARIS, France
1 program
1
TaxoterePhase 1/25 trials
Active Trials
NCT01008774Completed239Est. Oct 2011
NCT00493649Completed493Est. Apr 2013
NCT00231855Completed31Est. Mar 2007
+2 more trials
Alpha Tau Medical
Alpha Tau MedicalJERUSALEM, Israel
3 programs
DaRT seedsN/A1 trial
Diffusing Alpha Radiation Emitters TherapyN/A1 trial
Radiation: Diffusing Alpha Radiation Emitters TherapyN/A1 trial
Active Trials
NCT06615635Not Yet Recruiting28Est. Dec 2026
NCT03015883Completed28Est. Jun 2019
NCT05065346Not Yet Recruiting79Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Alliance PharmaceuticalsErlotinib
Coherus OncologyToripalimab-tpzi
Alliance PharmaceuticalsAtezolizumab
Alliance PharmaceuticalsAtezolizumab
Alliance PharmaceuticalsAtezolizumab
Boehringer IngelheimAfatinib 40 MG
AmgenInjection of TVEC into target lesions - week 1-2
Alliance PharmaceuticalsAtezolizumab
Karyopharm TherapeuticsSelinexor
Alliance PharmaceuticalsErlotinib
Alliance PharmaceuticalsErlotinib
Alliance PharmaceuticalsErlotinib
SanofiTaxotere
SanofiTaxotere
SanofiTaxotere

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 1,725 patients across 23 trials

NCT00362986Alliance PharmaceuticalsErlotinib

Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer

Start: Oct 2006Est. completion: Oct 2009116 patients
Phase 3Completed
NCT07214987Coherus OncologyToripalimab-tpzi

PDT For Induction Therapy For Head And Neck Cancer

Start: Mar 2026Est. completion: Sep 202926 patients
Phase 2Not Yet Recruiting
NCT06762808Alliance PharmaceuticalsAtezolizumab

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Start: May 2025Est. completion: Aug 20250
Phase 2Withdrawn
NCT06754501Alliance PharmaceuticalsAtezolizumab

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Start: Apr 2025Est. completion: Jul 20294 patients
Phase 2Active Not Recruiting
NCT05798663Alliance PharmaceuticalsAtezolizumab

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Start: Dec 2023Est. completion: Nov 2026178 patients
Phase 2Active Not Recruiting
NCT05070403Boehringer IngelheimAfatinib 40 MG

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Start: Oct 2021Est. completion: Mar 202825 patients
Phase 2Recruiting
NCT03714828AmgenInjection of TVEC into target lesions - week 1-2

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

Start: Dec 2018Est. completion: Jul 202311 patients
Phase 2Completed
NCT03102242Alliance PharmaceuticalsAtezolizumab

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

Start: Nov 2017Est. completion: Oct 202264 patients
Phase 2Completed
NCT02213133Karyopharm TherapeuticsSelinexor

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

Start: Sep 2014Est. completion: Dec 2015
Phase 2Terminated
NCT01009203Alliance PharmaceuticalsErlotinib

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Start: Dec 2009Est. completion: Dec 201213 patients
Phase 2Terminated
NCT00733746Alliance PharmaceuticalsErlotinib

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Start: Apr 2009Est. completion: Jun 2019123 patients
Phase 2Completed
NCT00550836Alliance PharmaceuticalsErlotinib

Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer

Start: Mar 2009Est. completion: May 2013104 patients
Phase 2Completed
NCT00493649SanofiTaxotere

Adj TC + Herceptin Early Stage Breast Cancer

Start: Jun 2007Est. completion: Apr 2013493 patients
Phase 2Completed
NCT00231855SanofiTaxotere

Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers

Start: Nov 2004Est. completion: Mar 200731 patients
Phase 2Completed
NCT00247988SanofiTaxotere

Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers

Start: Oct 2003Est. completion: Apr 200738 patients
Phase 2Terminated
NCT00059852Alliance PharmaceuticalsErlotinib

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Start: Jun 2003Est. completion: Jan 200961 patients
Phase 2Completed
NCT03387111ImmunityBioAldoxorubicin HCl

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Start: Jan 2018Est. completion: Jan 20214 patients
Phase 1/2Terminated
NCT00139243SanofiTaxotere

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

Start: Oct 1997Est. completion: Jan 200630 patients
Phase 1/2Completed
NCT00996515Alliance PharmaceuticalsErlotinib

A Phase 1 Protocol of 5-Azacytidine and Erlotinib in Advanced Solid Tumor Malignancies

Start: Jun 2008Est. completion: Sep 201130 patients
Phase 1Completed
NCT06615635Alpha Tau MedicalDaRT seeds

Clinical Study Protocol for Cutaneous SCC for Immunocompromised Patients

Start: Dec 2025Est. completion: Dec 202628 patients
N/ANot Yet Recruiting
NCT05065346Alpha Tau MedicalRadiation: Diffusing Alpha Radiation Emitters Therapy

Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC

Start: Mar 2025Est. completion: Jun 202679 patients
N/ANot Yet Recruiting
NCT03015883Alpha Tau MedicalDiffusing Alpha Radiation Emitters Therapy

Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma

Start: Feb 2017Est. completion: Jun 201928 patients
N/ACompleted
NCT01008774SanofiTaxotere

START: Swiss Taxotere Alopecia Prevention Trial

Start: Jul 2009Est. completion: Oct 2011239 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,725 patients
9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)